Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis

Cancer Research

Volumn 75, Issue 18, 2015, Pages 3699-3705

  Kirane, Amanda ^a   Ludwig, Kathleen F ^a   Sorrelle, Noah ^a,b   Haaland, Gry ^c   Sandal, Tone ^c   Ranaweera, Renate ^c   Toombs, Jason E ^a   Wang, Miao ^a   Dineen, Sean P ^a   Micklem, David ^d   Dellinger, Michael T ^a   Lorens, James B ^c   Brekken, Rolf A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d BerGenBio   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AXL RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; WARFARIN; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; DEOXYCYTIDINE; GEMCITABINE; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; CELL MOTION; DISEASE COURSE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETICS; GERMFREE ANIMAL; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL DIVISION; CELL LINE, TUMOR; CELL MOVEMENT; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG SYNERGISM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; WARFARIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942940565     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2887-T     Document Type: Article

References (21)

1. Brown JM. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res 1973;33:1217-24.
2. McCulloch P, George WD. Warfarin inhibition of metastasis: the role of anticoagulation. Br J Surg 1987;74:879-83.
3. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000;342:1953-8.
4. Song X, Wang H, Logsdon CD, Rashid A, Fleming JB, Abbruzzese JL, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 2011;117:734-43.
5. Nakano T, Kawamoto K, Kishino J, Nomura K, Higashino K, Arita H. Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells. Biochem J 1997;323:387-92.
6. Hafizi S, Dahlback B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J 2006;273:5231-44.
7. Hasanbasic I, Rajotte I, Blostein M. The role of gamma-carboxylation in the anti-apoptotic function of gas6. J Thromb Haemost 2005;3:2790-7.
8. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623-6.
9. Tsou WI,Nguyen KQ, Calarese DA, Garforth SJ, Antes AL, Smirnov SV, et al. Receptor tyrosine kinases, TYRO3, AXL, and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation. J Biol Chem 2014;289:25750-63.
10. PaolinoM, Choidas A,Wallner S, Pranjic B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 2014;507:508-12.
11. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7:829-40.
12. Ostapoff KT, Cenik BK, Wang M, Ye R, Xu X, Nugent D, et al. Neutralizing murine TGFbetaR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Res 2014;74:4996-5007.
13. Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M, et al. Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog 2007;46:155-64.
14. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small-molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010;70:1544-54.
15. Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 2012;31:1692-703.
16. Gjerdrum C, TironC, Hoiby T, Stefansson I, HaugenH, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-9.
17. RhimAD, Mirek ET, Aiello NM, Maitra A, Bailey JM,McAllister F, et al.EMT and dissemination precede pancreatic tumor formation. Cell 2012;148: 349-61.
18. ArumugamT, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 2009;69:5820-8.
19. Wilson C, Ye X, Pham TQ, Lin E, Chan SM, McNamara E, et al. AXL inhibition sensitizes mesenchymal cancer cells to anti-mitotic drugs. Cancer Res 2014;74:5878-90.
20. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19: 279-90.
21. Lew ED, Oh J, Burrola PG, Lax I, Zagorska A, Traves PG, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife 2014;3.